Literature DB >> 24506545

TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Dorota Jesionek-Kupnicka1, Malgorzata Szybka, Beata Malachowska, Wojciech Fendler, Piotr Potemski, Sylwester Piaskowski, Dariusz Jaskolski, Wielislaw Papierz, Wieslaw Skowronski, Waldemar Och, Radzislaw Kordek, Izabela Zawlik.   

Abstract

Reduced expression of TP53 by promoter methylation has been reported in several neoplasms. It remains unclear whether TP53 promoter methylation is associated with reduced transcriptional and protein expression in glioblastoma (GB). The aim of our work was to study the impact of TP53 methylation and mutations on TP53 mRNA level and protein expression in 42 molecularly characterized primary GB tumors. We also evaluate the impact of all molecular alterations on the overall patient survival. The frequency of TP53 promoter methylation was found in 21.4%. To the best of our knowledge, this is the first report showing such high frequency of TP53 promoter methylation in primary GB. There was no relation between TP53 promoter methylation and TP53 mRNA level (p=0.5722) and between TP53 promoter methylation and TP53 protein expression (p=0.2045). No significant associations were found between TP53 mRNA expression and mutation of TP53 gene (p=0.9076). However, significant association between TP53 mutation and TP53 protein expression was found (p=0.0016). Our data suggest that in primary GB TP53 promoter methylation does not play a role in silencing of TP53 transcriptional and protein expression and is probably regulated by other genetic and epigenetic mechanisms associated with genes involved in the TP53 pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24506545      PMCID: PMC3967380          DOI: 10.1089/dna.2013.2201

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  58 in total

1.  CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene.

Authors:  M Schroeder; M J Mass
Journal:  Biochem Biophys Res Commun       Date:  1997-06-18       Impact factor: 3.575

2.  Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas.

Authors:  R Soong; P D Robbins; B R Dix; F Grieu; B Lim; S Knowles; K E Williams; G R Turbett; A K House; B J Iacopetta
Journal:  Hum Pathol       Date:  1996-10       Impact factor: 3.466

3.  Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator.

Authors:  Elaine M Hurt; Suneetha B Thomas; Benjamin Peng; William L Farrar
Journal:  Cancer Biol Ther       Date:  2006-09-06       Impact factor: 4.742

4.  Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.

Authors:  I Wojcik; M Szybka; E Golanska; P Rieske; J Z Blonski; T Robak; J Bartkowiak
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

Review 5.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

6.  TP53 promoter methylation in human gliomas.

Authors:  Vishwa Jeet Amatya; Ulrike Naumann; Michael Weller; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2005-07-16       Impact factor: 17.088

7.  ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Authors:  Delin Chen; Ning Kon; Muyang Li; Wenzhu Zhang; Jun Qin; Wei Gu
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

8.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 9.  The p53 gene and its role in human brain tumors.

Authors:  O Bögler; H J Huang; P Kleihues; W K Cavenee
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

10.  Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.

Authors:  K Watanabe; K Sato; W Biernat; O Tachibana; K von Ammon; N Ogata; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Clin Cancer Res       Date:  1997-04       Impact factor: 12.531

View more
  11 in total

1.  Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosourea-induced thymic lymphoma in C57BL/6 mice.

Authors:  Xueyun Huo; Zhenkun Li; Shuangyue Zhang; Changlong Li; Meng Guo; Jing Lu; Jianyi Lv; Xiaoyan Du; Zhenwen Chen
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

2.  The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.

Authors:  Ji Hyung Hong; Kang San Roh; Sung-Suk Suh; Sukchan Lee; Sook Whan Sung; Jae Kil Park; Jae Ho Byun; Jin Hyoung Kang
Journal:  Tumour Biol       Date:  2015-06-25

3.  The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand.

Authors:  Arisara Poosari; Thitima Nutravong; Wises Namwat; Wiphawan Wasenang; Prakasit Sa-Ngiamwibool; Piti Ungareewittaya
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 4.  Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.

Authors:  Ana B Herrero; Elizabeta A Rojas; Irena Misiewicz-Krzeminska; Patryk Krzeminski; Norma C Gutiérrez
Journal:  Int J Mol Sci       Date:  2016-11-30       Impact factor: 5.923

5.  MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients.

Authors:  Dorota Jesionek-Kupnicka; Marcin Braun; Berenika Trąbska-Kluch; Joanna Czech; Małgorzata Szybka; Bożena Szymańska; Dominika Kulczycka-Wojdala; Michał Bieńkowski; Radzisław Kordek; Izabela Zawlik
Journal:  Arch Med Sci       Date:  2017-07-31       Impact factor: 3.318

Review 6.  Epigenetic Control of a Local Chromatin Landscape.

Authors:  Anna M Chiarella; Dongbo Lu; Nathaniel A Hathaway
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

7.  Pathway and network analysis of more than 2500 whole cancer genomes.

Authors:  Matthew A Reyna; David Haan; Marta Paczkowska; Lieven P C Verbeke; Miguel Vazquez; Abdullah Kahraman; Sergio Pulido-Tamayo; Jonathan Barenboim; Lina Wadi; Priyanka Dhingra; Raunak Shrestha; Gad Getz; Michael S Lawrence; Jakob Skou Pedersen; Mark A Rubin; David A Wheeler; Søren Brunak; Jose M G Izarzugaza; Ekta Khurana; Kathleen Marchal; Christian von Mering; S Cenk Sahinalp; Alfonso Valencia; Jüri Reimand; Joshua M Stuart; Benjamin J Raphael
Journal:  Nat Commun       Date:  2020-02-05       Impact factor: 14.919

Review 8.  A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer.

Authors:  Yuqing Xiong; Yun Zhang; Shunbin Xiong; Abie E Williams-Villalobo
Journal:  Biology (Basel)       Date:  2020-09-11

Review 9.  Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.

Authors:  Ainhoa Hernández; Marta Domènech; Ana M Muñoz-Mármol; Cristina Carrato; Carmen Balana
Journal:  Cells       Date:  2021-12-14       Impact factor: 6.600

Review 10.  Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma.

Authors:  Konstantinos Gousias; Theocharis Theocharous; Matthias Simon
Journal:  Biomedicines       Date:  2022-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.